ThirtyFiveBio aims to treat gastrointestinal cancer by targeting a so-called orphan receptor called GPR35. The biotech startup is revealing its science at the American Association of Cancer Research annual meeting.
Months into the Covid-19 pandemic, the pace of new investments for startups has picked back up. Five VCs shared what's changed and how they're working in the midst of the crisis.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
VCs from Sanofi Ventures, Canaan Partners and GE Ventures said increasing investment along with declining exit activity indicates a bubble in the industry.
The company aims to develop therapeutics focused on antibodies found in patients who respond well to cancer immunotherapies and develop treatments for those who do not.
Julie Grant went from associate to partner in a little over three years at Canaan Partners and now wants her understanding of science and corporate America to tame cancer and boost diversity in healthcare.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Boston-based Arrakis has officially launched with a $38 million Series A and a unique mission to bind RNA with small molecules.
But don't get too excited about on-demand house calls.
The three West Coast venture firms are teaming up to build a stealth new startup called Nexcida Therapeutics. They are developing therapeutics for infectious disease, but haven't disclosed anything else.
Hey, startups: I chatted this week at the J.P. Morgan conference with Brent Ahrens of Canaan Partners about the venture firm’s recent $675 million fund – it’s tenth and largest – and who they’re looking to fund. The majority will be doled out to the tech space, but the remaining – some $220 million – is allocated to […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Menlo Park venture firm Canaan Partners just raised $675 million for its tenth fund – with plans to invest this Fund X mostly in early stage and seed stage startups in both technology and health care. The majority of Canaan’s healthcare focus for this fund will continue to be therapeutics, Canaan partner Wende Hutton said, […]